Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C (BASIS)

This study has been completed.
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: December 19, 2012
Last updated: January 27, 2015
Last verified: December 2013
The purpose of this study is to determine if 48 weeks of therapy with Peginterferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Peginterferon alfa-2a plus Ribavirin.

Condition Intervention Phase
Hepatitis C Virus (HCV)
Biological: Peginterferon Lambda-1a
Drug: Ribavirin
Biological: Peginterferon alfa-2a
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 Chronic Hepatitis C Subjects

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Proportion of subjects who develop treatment emergent cytopenic abnormalities (anemia as defined by Hb < 10 g/dL, and/or neutropenia as defined by ANC < 750 mm3 and/or thrombocytopenia as defined by platelets < 50,000 mm3) in treatment-naive subjects [ Time Frame: Up to 48 weeks of treatment ] [ Designated as safety issue: Yes ]
    • ANC = Absolute Neutrophil Count
    • Hb = Hemoglobin

Secondary Outcome Measures:
  • Proportion of subjects with Sustained Virologic Response at Post-Treatment Follow-up Week 24 (SVR24), defined as Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) < Lower Limit of Quantitation of Assay (LLOQ) [ Time Frame: At Post-Treatment Follow-up Week 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects with Rapid Virologic Response (RVR) (HCV RNA not detected) [ Time Frame: On treatment Week 4 (of an up to 48-week treatment period) ] [ Designated as safety issue: No ]
  • Proportion of subjects with on-treatment Serious Adverse Events (SAEs) through end of treatment [ Time Frame: Up to 48 weeks of treatment ] [ Designated as safety issue: Yes ]
  • Proportion of subjects with dose reductions through end of treatment [ Time Frame: Up to 48 weeks of treatment ] [ Designated as safety issue: Yes ]
  • Proportion of subjects who discontinue due to Adverse Events (AEs) through end of treatment [ Time Frame: Up to 48 weeks of treatment ] [ Designated as safety issue: Yes ]
  • Proportion of subjects with on-treatment Interferon (IFN)-associated symptoms as determined by adverse event reporting [ Time Frame: Up to 48 weeks of treatment ] [ Designated as safety issue: Yes ]

    On-treatment IFN-associated symptoms are:

    • Flu-like symptoms (as defined by pyrexia or chills or pain)
    • Musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)
    • Neurological symptoms (headache or dizziness)
    • Constitutional symptoms (fatigue or asthenia)
    • Psychiatric symptoms (depression or irritability or insomnia)

Enrollment: 40
Study Start Date: March 2013
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Peginterferon Lambda-1a + Ribavirin
Peginterferon Lambda-1a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
Biological: Peginterferon Lambda-1a
Other Name: BMS-914143
Drug: Ribavirin
Other Name: Ribasphere
Active Comparator: Peginterferon alfa-2a + Ribavirin
Peginterferon alfa-2a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
Drug: Ribavirin
Other Name: Ribasphere
Biological: Peginterferon alfa-2a
Other Name: Pegasys


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic hepatitis C, Genotype 1
  • HCV RNA ≥100,000 IU/mL at screening
  • Liver biopsy documenting no cirrhosis (within prior 3 years). Where approved for staging of liver disease, non-invasive imaging may be used to assess the extent of liver disease
  • Naïve to prior anti-HCV therapy

Exclusion Criteria:

  • Infected with HCV other than Genotype 1
  • Positive Hepatitis B Surface Antigen (HBsAg), or Human Immunodeficiency Virus (HIV)-1/HIV-2 antibody at screening
  • Evidence of liver disease other than HCV
  • Active substance abuse
  • Use of hematologic growth factors within 90 days prior to study randomization
  • Evidence of history of cirrhosis based on radiologic criteria or biopsy results and clinical criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01754974

Czech Republic
Local Institution
Hradec Kralove, Czech Republic, 500 05
Local Institution
Praha 4, Czech Republic, 140 00
Local Institution
Usti Nad Labem, Czech Republic, 400 01
Korea, Republic of
Local Institution
Chungcheongnam-do, Korea, Republic of, 330-930
Local Institution
Daegu, Korea, Republic of, 700-821
Local Institution
Gangwon-do, Korea, Republic of, 200-704
Local Institution
Gyeonggi-do, Korea, Republic of, 420-717
Local Institution
Gyeonggi-do, Korea, Republic of, 463-707
Local Institution
Gyeongsangnam-do, Korea, Republic of, 626-770
Local Institution
Incheon, Korea, Republic of, 403-720
Local Institution
Seoul, Korea, Republic of, 156-755
Local Institution
Mexico, Distrito Federal, Mexico, 07760
Local Institution
Mexico City, Estado De Mexico, Mexico, 06700
Local Institution
Guadalajara, Jalisco, Mexico, 44500
Local Institution
Guadalajara, Jalisco, Mexico, 44650
Local Institution
Distrito Federal, Mexico, 03720
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: Bristol-Myers Squibb Identifier: NCT01754974     History of Changes
Other Study ID Numbers: AI452-033  2012-003508-11 
Study First Received: December 19, 2012
Last Updated: January 27, 2015
Health Authority: Korea: Food and Drug Administration
Brazil: National Health Surveillance Agency
Brazil: Ministry of Health
Brazil: National Committee of Ethics in Research
Czech Republic: State Institute for Drug Control
Hungary: National Institute of Pharmacy
Mexico: Ministry of Health
Poland: National Institute of Medicines
Poland: Ministry of Health
Poland: Ministry of Science and Higher Education
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Romania: National Medicines Agency
Russia: Ethics Committee
Russia: Ministry of Health of the Russian Federation
Russia: FSI Scientific Center of Expertise of Medical Application
Turkey: Ministry of Health

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Peginterferon alfa-2a
Anti-Infective Agents
Antiviral Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on May 24, 2016